Impact of integrase inhibitors on cardiovascular disease events in people with HIV starting antiretroviral therapy.
Bernard SurialFrédérique ChammartinJosé DamasAlexandra CalmyDavid HaerryMarcel StöcklePatrick SchmidEnos BernasconiChristoph A FuxPhilip TarrHuldrych F GünthardGilles WandelerAndri Rauchnull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
In this target trial emulation, we found no difference in short or longer term risk for CVD events between treatment-naïve PWH who started INSTI-based and those on other ART.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- cardiovascular disease
- hiv infected patients
- hiv aids
- clinical trial
- study protocol
- preterm infants
- type diabetes
- phase ii
- metabolic syndrome
- coronary artery disease
- men who have sex with men
- double blind
- south africa
- combination therapy
- gestational age